Boothbay Fund Management LLC Purchases 82,513 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

Boothbay Fund Management LLC lifted its position in QuidelOrtho Co. (NASDAQ:QDELFree Report) by 216.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 120,589 shares of the company’s stock after acquiring an additional 82,513 shares during the period. Boothbay Fund Management LLC’s holdings in QuidelOrtho were worth $5,372,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in QDEL. Blue Trust Inc. lifted its stake in QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company’s stock worth $58,000 after purchasing an additional 844 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of QuidelOrtho in the fourth quarter worth approximately $74,000. KBC Group NV lifted its stake in shares of QuidelOrtho by 122.9% during the 4th quarter. KBC Group NV now owns 3,437 shares of the company’s stock worth $153,000 after acquiring an additional 1,895 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in QuidelOrtho by 75.3% during the 4th quarter. Sterling Capital Management LLC now owns 3,726 shares of the company’s stock valued at $166,000 after acquiring an additional 1,601 shares during the period. Finally, LPL Financial LLC bought a new position in QuidelOrtho in the 4th quarter valued at $221,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Trading Up 1.1 %

NASDAQ QDEL opened at $28.09 on Friday. The company’s 50-day simple moving average is $33.62 and its two-hundred day simple moving average is $38.90. QuidelOrtho Co. has a one year low of $23.77 and a one year high of $49.45. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -0.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDELGet Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities analysts forecast that QuidelOrtho Co. will post 2.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on QDEL. Royal Bank of Canada decreased their target price on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a research report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an “underweight” rating for the company in a research report on Monday, April 21st. StockNews.com lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, UBS Group boosted their price target on QuidelOrtho from $43.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $46.83.

Get Our Latest Stock Report on QuidelOrtho

About QuidelOrtho

(Free Report)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Featured Articles

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Co. (NASDAQ:QDELFree Report).

Institutional Ownership by Quarter for QuidelOrtho (NASDAQ:QDEL)

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.